High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort
暂无分享,去创建一个
J. Maciejewski | U. Steidl | S. Goel | I. Braunschweig | B. Przychodzen | K. Gritsman | A. Shastri | I. Mantzaris | M. Janakiram | N. Kornblum | O. Derman | K. Pradhan | A. Verma | Y. Wang | J. Al-Hafidh | C. Hirsch | J. Hall | R. Battini | B. Halmos
[1] S. Nahas,et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.
[2] S. Miyano,et al. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. , 2015, Cancer cell.
[3] P. Campbell,et al. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes , 2015, Nature Communications.
[4] C. H. Bartlett,et al. Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia , 2015 .
[5] D. Neuberg,et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.
[6] D. Neuberg,et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[8] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[9] M. McDevitt,et al. TP53 Mutations in Myeloid Malignancies are either Homozygous or Hemizygous due to Copy Number-Neutral Loss of Heterozygosity or Deletion of 17p , 2009, Leukemia.